Quest Diagnostics Incorporated (DGX) Income Statement
An income statement shows a company's revenue, expenses, and profit over a reporting period.
Quest Diagnostics Incorporated provides diagnostic testing and services in the United States.
Total Revenue Chart for Quest Diagnostics Incorporated
Quest Diagnostics Incorporated (DGX) revenue for FY2025 was USD 11.0B, a 11.8% change from FY2024. Quest Diagnostics Incorporated's revenue grew from USD 1.6B in 1996 to USD 11.0B in 2025 (582.7% over 29 years). Earnings per share grew from USD 0.55 in 2000 to USD 8.74 in 2025 (1476.2%). Revenue compound annual growth rate: 5-year CAGR of 3.2%, 10-year CAGR of 3.9%, 20-year CAGR of 3.5%.
Total Revenue (US Dollars)
R&D as % of Revenue
Compare with
Key Stats
- Market Cap
- $26.32B
- Implied Share Price
- $238.50
- Enterprise Value
- $31.55B
- Revenue (TTM)
- $11.56B
- EBITDA
- $2.27B
- Profit Margin
- 9.19%
- Trailing P/E
- 25.35
- Forward P/E
- 20.96
- Price/Book (MRQ)
- 3.43
- Price/Sales (TTM)
- 2.28
- EV/EBITDA
- 14.01
- EV/Revenue
- 2.73
- Dividend Yield
- 1.41%
- Book Value
- $68.33
- Free Cash Flow (FY2025)
- $1.36B
- Free Cash Flow Yield
- 5.16%
Snapshot as of 6th August 2026 — not point-in-time controlled, may lag the live market by a few days.